Non-autoimmune combined factor XIII A and B subunit deficiencies in rheumatoid arthritis patients treated with anti-interleukin-6 receptor monoclonal antibody (tocilizumab)
An antibody to the IL-6 receptor (tocilizumab, TCZ) is an effective treatment for RA.
•
Two RA cases with acquired FXIII deficiency developed bleeding during TCZ treatment.
•
FXIII activity, FXIII-A, -B, and -A2B2 antigens were low in 36 TCZ-treated RA cases.
•
The low FXIII levels may result from their impaired synthesis caused by TCZ.
•
TCZ-treated patients may be at an elevated risk of bleeding because of low FXIII.
NGLC 2004-2010.National Geological Library of China All Rights Reserved.
Add:29 Xueyuan Rd,Haidian District,Beijing,PRC. Mail Add: 8324 mailbox 100083
For exchange or info please contact us via email.